Major Advancements in MASH Management

In this comprehensive and forward-looking session, Dr. Kwo shares key clinical insights on managing metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD). With the global prevalence of MASLD rising—impacting over a third of adults and up to 65% of individuals with type 2 diabetes—early detection and treatment are more critical than ever. This educational presentation, developed in collaboration with CLDF and the Global NASH Council, explores the latest approaches to noninvasive testing, including the use of FIB-4, ELF score, transient elastography, and MRI-PDFF to identify patients with advanced fibrosis and guide clinical decision-making. Dr. Kwo explains how to interpret liver stiffness measurements (LSM) and controlled attenuation parameters (CAP), offering practical guidance for applying these tools in real-world hepatology and GI settings. The presentation also addresses the foundational role of lifestyle modification—such as weight loss, dietary strategies like the Mediterranean diet and intermittent fasting, and physical activity—in slowing disease progression. Special attention is given to the role of GLP-1 receptor agonists in patients with type 2 diabetes or obesity, as well as the unique considerations in managing lean MASH. A major highlight of the session is the clinical application of resmetirom, the first FDA-approved therapy for non-cirrhotic MASH with moderate to advanced fibrosis. Dr. Kwo outlines who qualifies for treatment, how to initiate therapy, and what monitoring is required, while also exploring how future combination therapies may further advance outcomes for patients. With an eye toward both current practice and future innovation, this talk provides an actionable roadmap for clinicians who are increasingly encountering MASH and MASLD in routine care. This activity is jointly provided by the Chronic Liver Disease Foundation (CLDF) and the Global NASH Council through an educational grant from Madrigal Pharmaceuticals. #masld, #mash, #nash, #liverfibrosis, #noninvasivetesting, #fib4, #elfscore, #liverstiffness, #mrelastography, #pdff, #glp1agonist, #resmetirom, #lifestyleintervention, #bariatricsurgery, #cardiometabolichealth, #steatohepatitis, #fibrosisregression, #hepaticoutcomes, #leannash, #multidisciplinarycare